Compound News and Research

RSS

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has enrolled the first patient into its pivotal clinical trial with its new breakthrough compound of inhaled alpha-1 antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System (PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.

9 Feb 2010

States deal with small budgets, Medicaid cuts

Virginian-Pilot: Area hospitals are preparing "for a round of Medicaid spending cuts that executives say could be the worst in decades and lead to more cutbacks in their organizations. Rising health care costs and a surge in the number of Medicaid patients have increased the state's obligation to the government health insurance program for the poor and disabled by $777.7 million over two years.

9 Feb 2010

Genta commences Phase 2 trial of tesetaxel on first subject

Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in melanoma clinical research.

9 Feb 2010

AMRI announces fourth-quarter and full-year 2009 results

AMRI today reported financial and operating results for the fourth quarter and full year ending December 31, 2009.

8 Feb 2010

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Silence Therapeutics plc today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. Known as PKN-3, the target is a protein kinase C-related molecule that is believed to play an important role in the growth of cancer cells, as well as metastasis formation.

8 Feb 2010

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

An investigational drug that inhibits serotonin synthesis in the gut, administered orally once daily, effectively cured osteoporosis in mice and rats reports an international team led by researchers from Columbia University Medical Center, in the Feb. 7 issue of Nature Medicine.

7 Feb 2010

AMAG Pharmaceuticals releases safety update on Feraheme Injection

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection for intravenous use.

6 Feb 2010

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

Organized by Pharma IQ, a division of IQPC, the 4th Improving Solubility conference will be held March 29-31, 2010 at The Park Hyatt in Philadelphia, PA. This forum brings together pharmaceutical researchers and scientists to uncover advances in enhancing solubility, amorphous forms, bioavailability & lipid-based formulation of drugs.

From IQPC Ltd 5 Feb 2010

New class of compound could become effective antidepressant with minimal side effects

Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the world.

5 Feb 2010

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

BioMarin Pharmaceutical Inc. announced today that it has entered into a stock purchase agreement to acquire LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers.

4 Feb 2010

Molecular Devices brand re-launched into life sciences marketplace

Today, Molecular Devices, Inc.—now part of Danaher Corporation—re-launched the Molecular Devices brand into the life sciences marketplace. The renewed corporate brand is focused primarily on meeting customer needs and exceeding customer expectations, and includes an evolved visual identity system.

From Danaher 4 Feb 2010

New discovery lays foundation for development of new anti-HIV drugs

A team of scientists at The Scripps Research Institute has identified two compounds that act on novel binding sites for an enzyme used by the human immunodeficiency virus (HIV), the virus that causes AIDS.

4 Feb 2010

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

Fast growing Scottish biotech company Sistemic Ltd today announced that it had closed a series A funding round with lead investors ChimeraBio and the Scottish Enterprise Scottish Co-Investment Fund. The company will use the funding to further develop its proprietary SistemRNA compound-centric drug discovery technology. Using SistemRNA shortens the odds in drug discovery by enabling far more accurate prediction of potential drug indications, interactions and side effects.

4 Feb 2010

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

4 Feb 2010

New vaccine to prevent malaria infection shown promise to protect young children

A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients - young children - against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa.

4 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Arrowhead Research Corporation today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope’s lead compound for cartilage regeneration. The study’s authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope’s bioactive nanofiber system promotes the growth of new cartilage in a rabbit model. The treatment is engineered to repair cartilage defects by working with an animal’s own bone marrow stem cells to stimulate the production of new natural cartilage.

3 Feb 2010

Nanotope publishes preclinical data demonstrating cartilage regeneration

Arrowhead Research Corporation has announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration.

3 Feb 2010

New formulated soy product offers heart health benefits

Just in time for Heart Health Month, EcoNugenics introduces the newest in their scientifically formulated product line: CIRCUTOL™ Cardiovascular Health Support.

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

Compound News and Research

Kamada commences enrollment in European inhaled AAT clinical trial for alpha-1 antitrypsin deficiency

States deal with small budgets, Medicaid cuts

Genta commences Phase 2 trial of tesetaxel on first subject

AMRI announces fourth-quarter and full-year 2009 results

Silence Therapeutics strengthens patent portfolio of RNAi therapeutics in solid tumor treatment

Investigational drug for osteoporosis inhibits serotonin synthesis in the gut

AMAG Pharmaceuticals releases safety update on Feraheme Injection

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

New class of compound could become effective antidepressant with minimal side effects

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

Molecular Devices brand re-launched into life sciences marketplace

New discovery lays foundation for development of new anti-HIV drugs

Sistemic to develop SistemRNA compound-centric drug discovery technology with closed series A funds

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

New vaccine to prevent malaria infection shown promise to protect young children

Phase 2a clinical trial results of VX-809 in patients with CF announced

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Nanotope publishes preclinical data demonstrating cartilage regeneration

New formulated soy product offers heart health benefits

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News